Antje Rottmann

No ORCID on file · 7 papers in corpus · active 2018-2023

Study types

  • article 3
  • other 1
  • paratext 1
  • rct 1
  • review 1

Condition tags

  • endometriosis 6
  • chronic_pelvic_pain 1
  • infertility 1
other
Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers
European journal of drug metabolism and pharmacokinetics ·doi:10.1007/s13318-023-00866-0

BACKGROUND: Overactive adenosine triphosphate signaling via P2X3 homotrimeric receptors is implicated in multiple conditions. To fully understand the metabolism and elimination pathways of eliapixant, a study was conducted to assess the pha…

article 2023
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis
Drugs in R&D ·doi:10.1007/s40268-023-00427-5

INTRODUCTION: BAY1128688 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme implicated in the pathology of endometriosis and other disorders. In vivo animal studies suggested a potential therapeutic appli…

rct 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
European journal of endocrinology ·doi:10.1093/ejendo/lvad063

OBJECTIVE: Aldo-keto reductase 1C3 (AKR1C3) has been postulated to be involved in androgen, progesterone, and estrogen metabolism. Aldo-keto reductase 1C3 inhibition has been proposed for treatment of endometriosis and polycystic ovary synd…

review 2022
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview
Clinical pharmacokinetics ·doi:10.1007/s40262-021-01073-3

Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavail…

article 2019
Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis
Journal of medicinal chemistry ·doi:10.1021/acs.jmedchem.8b01862

The presence and growth of endometrial tissue outside the uterine cavity in endometriosis patients are primarily driven by hormone-dependent and inflammatory processes-the latter being frequently associated with severe, acute, and chronic p…

article 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
ChemMedChem ·doi:10.1002/cmdc.201800487

Progesterone plays an important role in the female reproductive system. However, there is also evidence that gynecologic disorders/diseases such as uterine fibroids and endometriosis are progesterone-dependent. Steroidal and non-steroidal s…

paratext 2018
Front Cover: Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies (ChemMedChem 21/2018)
·doi:10.1002/cmdc.201800681

The Front Cover shows vilaprisan, a highly selective progesterone receptor modulator (SPRM), bound to the progesterone receptor (PR). Gynecologic diseases such as uterine fibroids and endometriosis depend on progesterone receptor function. …